Introduction Human V 2V 2 T cells play important role in immunity to infection and cancer by monitoring self and foreign isoprenoid metabolites with their T cell antigen receptors. Like CD4 and CD8
T cells from normal donors showed potent cytotoxicity. To investigate further, we compared the phenotypic characteristics of V 2V 2 T cells from 96 patients with NPC and 54 healthy controls. The fraction of late eVector memory V 2V 2 T cells (T EM RA ) was signiWcantly increased in NPC patients with corresponding decreases in the fraction of early memory V 2V 2 T cells (T CM ) compared with those in healthy controls. Moreover, T EM RA and T CM V 2V 2 cells from NPC patients produced signiWcantly less IFN-and TNF-, potentially contributing to their impaired cytotoxicity. Radiotherapy or concurrent chemoradiotherapy further increased the T EM RA V 2V 2 T cell population but did not correct the impaired production of IFN-and TNF-observed for T EM RA V 2V 2 T cells. Conclusion We have identiWed distinct alterations in the V 2V 2 T cell subsets of patients with NPC. Moreover, the overall cellular eVector function of T cells is compromised
Introduction
Human T cells are a unique subset of T cells that constitute 1-5% of peripheral blood T cells. The V 2 chain of the T cell receptor (TCR) usually pairs with the V 2 chain to form the V 2V 2 TCR (also termed V 9 V 2 TCR), which is expressed by the majority of circulating T cells [31, 32] . V 2V 2 T cells are present in low numbers at birth but expand during infancy due to environmental stimuli [36] . Preferential expansion of V 2V 2 T cells has been observed during a number of microbial infections [31] . The stimulating microbial antigens have been shown to be small nonpeptide metabolites (commonly termed phosphoantigens) essential for isoprenoid biosynthesis. We and others have demonstrated that the most potent natural microbial antigen for V 2V 2 T cells is (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) [21, 37, 39] . HMBPP is a microbial metabolite in the methyl erythritol phosphate pathway responsible for isoprenoid biosynthesis that is used by most Eubacteria and Apicomplexan parasites [31] . The major human antigen reported for V 2V 2 T cells is isopentenyl pyrophosphate (IPP) [51] , which is increased in some malignant cells and in almost all cells upon pharmacological treatment with bisphosphonates [16, 52] or alkylamines [31] .
Unlike CD4 and CD8 T cells, the majority of adult peripheral blood V 2V 2 T cells express various phenotypic markers generally found on memory cells [9] . Similar to CD4 and CD8 T cells, these memory V 2V 2 T cells are heterogeneous and multiple cell subsets can be distinguished based on their maturation surface markers and functional activities [5] . Various cell surface receptors have been used to divide memory cells into subsets. One criterion primarily used for human CD4 T cells has been the expression of the CCR7 chemokine receptor, which is required for lymph node homing [41, 42] . CD4 central memory T cells (T CM ) express CCR7, whereas eVector memory cells (T EM ) do not. In addition to CCR7 [14], we and others have found that the expression of CD27, CD28, CD45RA, and CD45RO molecules also serves to distinguish memory T cell and CD8 T cells subsets [1, 2, 19, 50] . Central memory CD8
T cells (T CM , also termed early memory cells by Appay [1] ) were identiWed as CD28 + CD27
+ CD45RA ¡ cells and also included early eVector cells [50] that secrete IFN-and TNF-but have little or no cytolytic activity due to low perforin expression [19, 50] . On rare occasions, CD8
T cells in the central memory pool lose CD27, but retain CD28 expression as well as other central memory cell properties (T CM 27¡ ) [2] . In contrast, eVector memory T cells (T EM , also termed intermediate memory cells) lack CCR7 and CD28, but continue to express CD27. Additionally, T EM also produce low levels of cytokines, but intermediate levels of perforin [50] . Late eVector memory T cells (T EM RA , also termed CD45RA + late memory cells) lack both CD28 and CD27 expression and represent terminally diVerentiated eVector T cells that express a high level of perforin, but demonstrate limited proliferative capacity.
Upon activation, V 2V 2 T cells kill a broad range of tumor cells, including lymphoma cells, leukemia cells, and other malignant hematological cells. V 2V 2 T cells can also kill a variety of solid tumors, including nasopharyngeal carcinoma [56] [44] . Moreover, adoptively transferred V 2V 2 T cells exhibit anti-tumor activity in various xenograft mouse models [22, 30, 56] . There is increasing evidence for the use of V 2V 2 T cells in cancer immunotherapy. In one study, stimulation of V 2V 2 T cells with the bisphosphonate drug pamidronate in combination with IL-2 led to partial remission and stable disease in some patients with refractory or relapsing B cell malignancies [54] . In a second study, the bisphosphonate, zoledronate, together with IL-2 was used to treat patients with metastatic prostate carcinoma [12] . A higher proportion of the treated patients demonstrated partial remission or stable disease and those patients with the highest numbers of V 2V 2 T cells exhibited the lowest levels of prostatespeciWc antigen, a cancer cell marker [12] . These Wndings suggest that V 2V 2 T cells may play a role in tumor immunosurveillance, as well as the possibility of employing these T cells in cancer immunotherapy.
Materials and methods

Patients and healthy controls
Venous blood samples were obtained from patients with nasopharyngeal carcinoma diagnosed at the National Cancer Center of Singapore. Healthy controls (NOR) were recruited from the Center for Transfusion Medicine, Health Sciences Authority of Singapore. Approval from the Institutional Review Board was obtained for the present protocol prior to the collection of blood samples from healthy individuals and NPC patients. A total of 96 NPC patients and 54 healthy donors were included in this study. The diagnosis of NPC was determined based on histopathological analysis. Clinical characteristics including gender, age, and tumor size and staging of cancer patients at the time of diagnosis were obtained from medical records (Table 1 ). Of the 96 NPC patients, 69 were male and 27 were female with a median age of 50 (range 29-77); whereas the healthy donors comprised 45 males and 9 females with a median age of 37.5 (range 22-59).
Isolation of PBMC and FACS staining PBMC were isolated by Ficoll-Paque density centrifugation. The following monoclonal antibodies were used: FITC-or PE-labeled V 2 (B6.1), FITC-labeled CD8 (RPA-T8), PE-labeled CD27 (M-T271), APC-labeled CD27 (0323), PE-Cy5-labeled CD28 (28.2), PE-Cy7-labeled CD28 (28.2), R-PE-labeled CD3 (HIT3a), and PE-Cy7-labeled CD3 (SK7). All Abs used in the present study were purchased from BD Biosciences (San Jose, CA, USA). Three-and four-color Xow cytometry were performed and analyzed using a FACSCalibur or a FACSCantoII Xow cytometer (BD Biosciences).
MACS isolation of V 2V 2 T cells PBMC were incubated with FITC anti-V 2 TCR mAb on ice for 30 min. Cells were washed once with chilled 2% FCS to remove excess unbound mAb. Anti-FITC MicroBeads were added and the cells were incubated on ice for another 30 min. The magnetic isolation of V 2 T cells was performed as described in the manufacturer's instructions (Miltenyi Biotech). These cells were subsequently passed through magnetic columns that separate non-V 2 T cells from V 2 T cells. The purity of the V 2 T cells was determined by Xow cytometry.
Cytotoxicity assay CTL assays were performed using DELFIA EuTDA Cytotoxicity Reagents (Perkin-Elmer) according to the manufacturer's instructions. BrieXy, 5 £ 10 3 K562 cells were labeled with a Xuorescence enhancing ligand, (bis (acetoxymethyl) 2,2Ј:6Ј,2Љ-terpyridine-6,6Љ-dicarboxylate (BATDA), in 1 ml of culture medium at 37°C for 30 min. The cells were washed four times with PBS and adjusted to 5 £ 10 4 cells/ml. One hundred microliter aliquots containing 5 £ 10 3 cells each were then plated in 96-well round bottom plates. PuriWed V 2V 2 T cells were added at the indicated E:T ratio and centrifuged at 100£g for 2 min. The plates were incubated for 2 h at 37°C. After incubation, the plates were centrifuged at 100£g for 2 min. Twenty microliters of supernatant was transferred to 96-well Xat bottom plates, followed by the addition of 180 l of the provided europium solution. The plates were then shaken for 15 min at RT. The Xuorescence intensity was measured using a time-resolved Xuorometer (VICTOR 3 ). The percentage of speciWc lysis was calculated as: % speciWc lysis = 100 £ (experimental release ¡ spontaneous release)/(maximum release ¡ spontaneous release). The background signal was subtracted from the maximum and spontaneous release values before the values were used to calculate the percentage of speciWc lysis.
Flow cytometric detection of intracellular cytokines
PBMC were plated at 1 £ 10 5 cells/well in 96-well roundbottom tissue culture plates in complete RPMI 1640 medium with or without HMBPP (0.316 M) for 4 h in the presence of Brefeldin A (GolgiPlug, BD Biosciences). To determine the full cytokine capability of CD8 T cells, PBMC were stimulated with PMA (10 ng/ml) and ionomycin (1 M) under the same conditions. After stimulation, the cells were harvested and stained with FITC-labeled anti-V 2 or FITC-labeled CD8, APC-labeled anti-CD27, and PE-Cy7-labeled anti-CD28. Cells were washed twice in staining buVer and subsequently Wxed in 100 l of 1£ BD CytoWx/Cytoperm for 20 min on ice. After Wxation, the cells were washed twice with 1£ permeabilization buVer, followed by cytoplasmic staining with PE-conjugated anti-TNF-(MAB11) or PE-conjugated anti-IFN-(4S.B3), both from BD Biosciences. The percentage of cytokineproducing V 2 or CD8 T cells among the four V 2V 2 T cell subsets was determined by four-color cytometry. A total of 100,000-150,000 events were acquired for each sample and analyzed using CellQuest Pro (BD Biosciences) and FlowJo 8.5.2 (TreeStar).
Statistical analyses
Data obtained for diVerent V 2V 2 T cell subsets were analyzed by one-way ANOVA using GraphPad Prism 4.0 software. Results are presented as scatter plots in which each dot represents either a healthy donor or a NPC patient.
Comparisons between groups were performed using a nonparametric Mann-Whitney U test. A P value <0.05 was considered signiWcant.
Results
V 2V 2 T cells from NPC patients exhibit a signiWcant reduction in tumor-speciWc cytotoxicity
To compare the cytolytic activity of V 2V 2 T cells from NPC patients and healthy controls (NOR), highly puriWed T cells were incubated with K562 (a T cell-sensitive cell line) or HK-1 (a human NPC cell line). Due to their low frequencies in peripheral blood, V 2V 2 T cells were isolated from 6 NPC patients and 5 NOR and pooled into their respective groups. The T cells from NPC patients demonstrated lower cytolytic activity against both K562 and HK-1 compared with those from NOR ( Fig. 1a, b) . The cytotoxicity assay represents a single experiment that was performed using pooled V 2V 2 T cells from NPC patients and NOR. A comparison of the frequency of V 2V 2 T cells from 96 patients with active NPC disease and 54 NOR revealed no signiWcant diVerence in the total percentage of V 2V 2 T cells between NPC patients and NOR (Fig. 1c) . The median frequency of V 2V 2 T cells detected in NPC patients and NOR was 1.8% (range 0.03-16.2%) and 2.0% (range 0.3-10.7%), respectively. Although the incidence of NPC is 2-3 times more common in males than in females, we could not detect any sex-related diVerence in the total number of V 2V 2 T cells between the two genders ( Fig. 1d ).
DiVerential regulation of the various T cell subsets of V 2V 2 T cells in NPC patients
Using CD27 and CD28, V 2V 2 T cells can be delineated into four distinct subsets: (Fig. 2) . Similar to CD8 + T memory cells, we and others have previously suggested that T CM cells predominantly represent early memory V 2V 2 T cells, whereas T EM RA cells are predominantly late memory V 2V 2 T cells [1] . In support of this, T EM RA cells have been shown to possess the highest level of perforin expression among the four T cell subsets, suggesting that T EM RA cells have higher cytolytic activity towards tumor cells than the other T cell subsets. Circulating V 2V 2 T cells are very heterogeneous, and the ability to identify cellular subsets based on CD27 and CD28 expression (Fig. 2a) may oVer an opportunity to "Wne-tune" the eVector immune functions of T cells during immunotherapy for NPC.
We examined the proportions of the various V 2V 2 T cell subsets in NPC patients. The major V 2V 2 cell subset present in the peripheral blood of both NPC patients and NOR was T CM cells. The median frequency of T CM V 2V 2 cells in NOR was 61.8% (range 12.1-91.7%). The median frequency of T CM V 2V 2 cells in NPC patients was 42.7% (range 0.7-86.8%), a signiWcantly lower frequency compared to NOR (Fig. 2b) . In contrast, the median frequency of late eVector memory cells (T EM RA ) was 25.2% (range 0-98.4%), which was signiWcantly higher in comparison to NOR, because the median frequency of T EM RA in NOR was 10.7% (range 0.3-69.4%). The increased T EM RA cells and decreased T CM cells in NPC patients were not related to age (Fig. 2c) because linear regression analyses showed no correlation between the frequencies of these two subsets and age in both NPC patients and NOR. Interestingly, the median frequency of T CM cells in NOR was marginally lower (P = 0.0447) in males than in females ( Figure S1 ). However, this was not observed in NPC patients. Overall, there was no observable diVerence in the total circulating V 2V 2 T cells between NPC patients and NOR; however, a speciWc and signiWcant reduction in the T CM cells and an increase in the T EM RA cells could be detected in NPC patients.
DiVerential expression of the various T cell subsets of V 2V 2 T cells is independent of the histological subtype and tumor stage of NPC UndiVerentiated carcinoma (UNC, WHO type III) and nonkeratinizing squamous cell carcinoma (SCC, WHO type II) are the two most common types of NPC in southeast Asia, including Singapore. Among the NPC specimens studied, 73 were UNC type and 23 were SCC type. When compared individually, there was no signiWcant diVerence in the total percentage of V 2V 2 T cells among patients with UNC or SCC compared with normal controls ( Figure S2a ). However, when the various V 2V 2 T cell subsets were studied, T CM cells were signiWcantly reduced in patients with UNC or SCC compared with normal controls ( Figure S2b) . The median frequency of T CM cells in patients with UNC was 43.5% (range 0.7-86.8%), whereas patients with SCC exhibited a median frequency of 41.3% (range 10.5-85.1%). The median frequency of T EM RA cells in UNC patients was 23.1% (range 0-98.4%), a signiWcant increase compared to NOR (Fig. 4b) . A similar increase was noted in T EM RA cells in SCC patients [median frequency of 29.5% (range 1.2-71%)]. This diVerence was slightly below statistical signiWcance (P = 0.0759) ( Figure S2b) .
Similar comparisons were performed after segregating the NPC specimens according to their clinical, nodal, and overall disease staging. Although a similar trend of decreased T CM cells and increased T EM RA cells was observed (Figures S3), these diVerences were not statistically signiWcant due to the limited number of specimens available for each of the clinical sub-groups.
Perforin is highly expressed in the T EM and T EM RA V 2V 2 T cell subsets of NOR and NPC patients V 2V 2 T cell-mediated killing of tumor targets is mediated by the release of stored perforin upon contact with tumor cells. To determine if there were diVerences in perforin (Fig. 3a, left panel) . The median proportions of T EM and T EM RA V 2V 2 T cells that expressed perforin were 77.2% (range 31.1-94.0%) and 89.7% (range 40.0-96.7%), respectively. These proportions were signiWcantly higher than those of early memory T CM cells (median 31.3%, range 5.1-83.4%) and T CM 27¡ cells (median 37.5%, range 11.9-89.4%) (Fig. 3a, right panel) . Similar to healthy controls (NOR), a greater proportion of T EM and T EM RA V 2V 2 T cells expressed perforin compared with T CM and T CM 27¡ cells from NPC patients (n = 10) (Fig. 3b) . However, a signiWcantly greater proportion of T CM cells from NPC patients expressed perforin compared with T CM cells from healthy controls (P = 0.029). No statistically signiWcant diVerences were detected in the other T cell subsets (Fig. 3b) .
Production of IFN-and TNF-by T CM and T EM RA V 2V 2 T cells is signiWcantly impaired in patients with active NPC disease
To determine the functional capabilities of T cells from NPC patients compared with healthy controls, V 2V 2 T cells were stimulated with HMBPP in which IFN-and TNF-production were measured by intracellular staining (Fig. 4a, left panel) . The proportion of V 2V 2 T cells producing IFN-and TNF-in NPC patients was signiWcantly lower than in healthy controls (Fig. 4a, right panel) . For NPC patients, the median percentage of IFN--and TNF--positive V 2V 2 T cells was 17.4% (range 3.4-46.4%) and 17.0% (range 3.4-45.2%), respectively (Fig. 4a, right  panel) . In contrast, the median percentage of IFN--and TNF--positive V 2V 2 T cells in NOR was 26.9% (range 10.5-46.4%) and 23.4% (range 11.7-56.2%), respectively (Fig. 4a, right panel) . To further delineate whether a speciWc T cell subset within the V 2V 2 T cells contributed to the overall impairment of cytokine production, IFN-and TNF-production by the various T cell subsets was evaluated in NPC patients and NOR. In NPC patients, the proportion of IFN--positive V 2V 2 T cells was signiWcantly reduced in all four subsets, with the T CM and T EM RA subsets demonstrating the most severe reductions (Fig. 4b) . Whereas the median proportion of IFN--positive T CM cells in NPC patients was 18.6% (range 5.4-57.1%), it was 32.7% (range 17.3-58.4%) in NOR. The median proportion of IFN--positive T EM RA cells in NPC patients was 9.6% (range 5.4-22.5%) compared with 19.8% (range 4.8-47.4%) in NOR (Fig. 4b) . When compared to NOR, the proportion of TNF--positive T CM and T EM RA cells in NPC patients was also signiWcantly reduced (Fig. 4b) . The median percentage of TNF--positive T CM cells detected in NPC patients was 19.2% (range 3.5-49.4%) compared with 28.7% (range 13.2-66.6%) in NOR. Similarly, the median percentage of TNF--positive T EM RA cells detected in NPC patients was 7.18% (range 0-67.1%), in contrast to 18.8% (range 0-40.6%) in NOR (Fig. 4b) .
Linear regression analyses showed no correlation between the number of cytokine-producing T cells and the age of the NPC patients or healthy controls (Fig. 4c) . This shows that the reduction in cytokine-producing T cells in NPC patients was not due to diVerences in the ages of the NPC patients and the healthy controls.
To determine the maximum cytokine-producing capability of T cells and CD8 T cells in response to mitogenic stimuli, PBMC from NPC patients and NOR were stimulated with PMA and ionomycin. Similar proportions of IFN-and TNF--positive CD8 T cells were detected in NPC patients and NOR (Fig. 4d) . There was also no signiWcant diVerence in the proportion of cytokine-positive V 2V 2 T cells between NPC patients and NOR. These results suggest that the reduced cytokine production of T cells from NPC patients in response to the HMBPP antigen is caused by a defect in TCR signaling.
Radiotherapy or concurrent chemo-radiotherapy increases the proportion of T EM RA cells in NPC patients but fails to correct cytokine production NPC patients with low-grade tumors respond well to radiotherapy. However, the response rate for NPC patients with tumor grades of 3-4 is poor and concurrent chemo-radiotherapy is usually introduced to improve the clinical outcome for these patients. To determine whether these treatments could normalize the T cell subset distributions and T cell function in NPC patients to those observed in healthy controls, PBMC were obtained from NPC patients 3-6 months after receiving their last treatment and the various V 2V 2 T cell subsets assessed. Instead of normalizing, the percentage of V 2V 2 T CM cells dropped even further to very low levels with a corresponding rise in the percentage of T EM RA cells (Fig. 5a) .
When the total proportion of IFN--and TNF--positive V 2V 2 T cells was analyzed in healthy controls, NPC patients prior to therapy, and NPC patients post-therapy, the proportion of IFN--and TNF--positive V 2V 2 T cells continued lower post-therapy than healthy controls with no evidence of improvement when compared with patients prior to therapy (Fig. 5b) . Further analysis of the various T cell subsets showed slight restoration of IFN--positive T CM cells in NPC patients following treatment (P = 0.0478). However, the impaired IFN-production observed for T EM RA cells and the production of TNF-by both T CM and T EM RA cells were not corrected following treatment (Fig. 5c) .
Discussion
V 2V 2 T cells have recently been exploited to provide protective immunity against intracellular pathogens and cancer [4] . In the present study, we show that V 2V 2 T cells from NPC patients are functionally impaired with respect to both their ability to kill tumor cells and their capacity to produce IFN-and TNF-. These functional defects are associated with alterations in the distribution of the various V 2V 2 T cell subsets. Immunophenotypic analyses of PBMC from NPC patients and healthy controls demonstrated that, although there was no diVerence in the total percentage of V 2V 2 T cells, the distribution of V 2V 2 T cell subsets was altered in NPC patients compared with healthy controls.
DiVerences in the expression of the costimulatory receptors CD28 and CD27, deWne 4 subsets of V 2V 2 T cells in NPC patients and healthy controls. Both naïve and central memory CD8
T cells express CD28 and CD27 [40] . Naïve T cells can be further discriminated from central memory cells because naïve T cells express both the CD45RA isoform and the lymph node homing receptor, CCR7, whereas central memory cells retain CCR7 but lack CD45RA [40, 42] . In most healthy controls and some NPC patients, CD28 + CD27 + V 2V 2 T cells represent the majority of T cells. However, unlike CD8 T cells, very few naïve V 2V 2 T cells are present in the peripheral blood of adult individuals. De Rosa et al. showed that naïve V 2V 2 T cells were CD45RO ¡ , CD11a low , and CD27 high and the percentage of CD27 high cells falls below 10% after 1 year of age [9] . Because it is technically diYcult to consistently discriminate CD27 high from CD27 low based on CD28 and CD27 staining, we are unable to determine the exact proportion of naïve V 2V 2 T cells. We determined CD28 + CD27 + V 2V 2 T cells to represent predominantly memory cells. This is in agreement with an earlier study showing that the predominant population of V 2V 2 T cells in the peripheral blood was CD45RO + CD45RA ¡ CD27 + [11] . Similar to CD8 central memory T cells, CD45RA
¡ CD27 + V 2 T cells also express CD62L and CCR7 [42] . Our results showed that in NPC patients the CD28 + CD27 + (T CM ) V 2V 2 T cell subset was markedly reduced whereas the CD28 ¡ CD27 ¡ (T EM RA ) V 2V 2 T cell subset was signiWcantly increased.
Similar CD8 T cells diVerentiation has been shown to correlate with disease progression in patients with viral infections [1] . For instance, HIV-infected long-term nonprogressors are characterized by an increase of highly proliferative CD27 + CD28 + HIV-speciWc memory CD8 T CM cells [35] . In contrast, other persistent viral infections deplete CD8
T CM cells by driving their diVerentiation to the CD27 ¡ CD28 ¡ terminally diVerentiated phenotype [35] . The observed reductions in T CM cells and increases in T EM RA V 2V 2 T cells in NPC patients is likely due to a similar diVerentiation of T CM cells. However, it is unclear whether this diVerentiation is due to a concurrent viral infection or is driven by the presence of the NPC only.
EBV infection is one possible viral cause of terminal diVerentiation of V 2V 2 T cells in NPC patients. The development of NPC in EBV-endemic regions is highly associated with latent EBV infections. Primary EBV infection in childhood usually manifests as an asymptomatic infection. In developed countries, however, not all individuals are infected in childhood. Primary EBV infection in adolescents and adults can then result in acute infectious mononucleosis. Acute infectious mononucleosis is associated with T cell expansions [8, 20] . Moreover, V 1 T cells proliferate in response to stimulation by EBV-transformed B lymphocytes [18, 34] . However, when we compared the percentage of V 1 + cells in NPC patients and healthy controls, we did not observe a signiWcant expansion in the V 1 + population in NPC patients (P = 0.2291). It is therefore unlikely that the decline in T CM V 2V 2 T cells in NPC patients is caused by changes in V 1 T cells. For PT patients, the percentages of T EM RA V 2V 2 T cells were signiWcantly higher than for NOR and PRE subjects. Increased T EM RA in PT was accompanied by a decline in early memory T CM V 2V 2 T cells. b Treatment failed to correct the defective IFN-and TNF-production detected for total V 2 T cells. c IFN-and TNFproduction by V 2V 2 T cell subsets remained defective, although IFN-production by T CM cells from PT patients showed a marginal increase compared with NPC patients before therapy V 2V 2 T cells in NPC patients that parallels the increase in late-diVerentiated CMV-speciWc CD8
T cells observed in patients with CMV infection. Thus, CMV infection is another possible cause for the terminal diVerentiation of V 2V 2 T cells in NPC patients. Consistent with this hypothesis, CMV infection is endemic in Singapore. For example, when 120 antenatal Singaporean women were screened for CMV infection, 87% tested seropositive [55] . Moreover, T cells expand in kidney transplant recipients developing CMV infection. However, against this hypothesis, these expansions are restricted to V 1 and V 3 T cells, not V 2V 2 T cells [10] . In our study, NPC patients were not tested for CMV seropositivity. Therefore, we were unable to determine if CMV seropositivity correlated with the observed changes in the V 2 T cell subset distribution.
The increased levels of T EM RA cells in NPC patients could be due to increased apoptosis of T CM V 2 T cells. However, this explanation seems less likely because T CM cells express higher levels of the anti-apoptotic protein bcl-2 compared with T EM and T EM RA cells [6] . This argues against the suggestion that the increased sensitivity of T CM cells to apoptosis could account for the loss of T CM cells in NPC patients. Furthermore, gag-speciWc CD27 + , but not CD27 ¡ , CD8 T cells persist in HIV-infected patients following adoptive transfer suggesting that the expression of CD27 on memory T cells may confer a survival advantage in vivo [33] . Therefore, the increased number of T EM RA cells in NPC patients may result from the diVerentiation of T CM to T EM RA cells with the loss of CD27 and CD28 expression due to viral or tumor eVects. Alternatively, the increased levels of T EM RA cells could simply be a consequence of the preferential expansion of T EM RA cells in NPC patients although this has never been described.
Previously, an age-related decrease in T cells [15] and an increase in the CD27 ¡ CCR7 ¡ eVector/memory V 2V 2 cells was reported for healthy donors [38] . Furthermore, the increased number of CD27 ¡ V 2 T cells negatively correlated with the ability to expand in response to IPP and IL-2 [38] . In the present study, there was no correlation between the levels of T CM or T EM RA V 2 T cells and the age of the NPC patients or healthy controls. Similarly, there was no correlation between the proportion of cytokine-positive V 2V 2 T cells and the age of NPC patients or healthy controls. Thus, the reduced number of cytokine-producing T CM and T EM RA in NPC patients compared with healthy controls is not due to diVerences in their ages.
V 2V 2 T cells can be activated to produce large amounts of TNF-and IFN-after stimulation by phosphoantigens [26, 27, 45] . Here we demonstrated that fewer V 2V 2 T cells from NPC patients produced IFN-and TNF-upon stimulation with the HMBPP antigen compared with V 2V 2 T cells obtained from healthy controls. However, mitogenic stimulation using PMA and ionomycin did not show the same decline in the numbers of IFN-producing cells suggesting that the decrease in cytokine production by V 2V 2 T cells is due to alterations in T cell receptor signaling following antigen presentation. The impaired production of cytokines by T CM and T EM RA T cells from NPC patients may reXect general V 2V 2 T cell dysfunction. There also may be an increased susceptibility to tumorogenesis since IFN-deWciency in mice makes them more susceptible to the development of lymphomas [48] and epithelial malignancies [49] .
IFN-secretion does not always correlate with cytotoxicity [47] . Using a single-cell assay that simultaneously measures cytotoxicity and IFN-secretion, Snyder et al. found that these two eVector functions could be regulated independently [46] . In the present study, however, the reduced frequency of IFN--and TNF--producing V 2V 2 T cells in NPC patients was also associated with lower cytotoxicity against tumor cells. Thus, the impairments that lead to the decreased production of IFN-and TNF-by V 2V 2 T cells from NPC patients may also aVect V 2V 2 T cell cytotoxicity. These functional defects could potentially limit the ability of V 2 T cells to mount eVective responses against tumor cells. However, it remains unclear whether the loss of function and altered subset distribution of V 2V 2 T cells in NPC patients reXect a general alteration in all circulating T cells including T cells. Further studies are needed to address this possibility.
NPC are relatively radiosensitive and, therefore, radiation is a standard modality of treatment for NPC. For NPC patients with advanced disease, combined radiotherapy and chemotherapy is often administered to improve clinical outcome and survival rates. Although these are useful modalities for NPC treatment, neither treatment restored V 2V 2 T cell function or returned V 2V 2 T cell subset distributions to normal.
Recent advances in immunotherapy speciWcally targeting T cells have shown promise for the treatment of multiple myeloma [54] , renal cell carcinoma [3] , and prostate cell carcinoma [12] . Large-scale ex vivo expansion of V 2V 2 T cells to provide an adequate source of cells for adoptive immunotherapy is now feasible [43] . The present study shows that alterations in the proportions of the V 2V 2 T cell subsets and their functions could have profound eVects on overall V 2V 2 T cell responses. Thus, monitoring V 2V 2 T cell subset distributions and functions may allow predictions about the eVectiveness of V 2V 2 T cell immunotherapy. Such monitoring oVers a rational basis for assessing the potential eVectiveness of immunotherapy strategies using V 2V 2 T cells to optimize for the best clinical outcome.
